BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/27/2025 9:21:15 AM | Browse: 445 | Download: 938
Publication Name World Journal of Hepatology
Manuscript ID 108533
Country China
Received
2025-04-17 11:16
Peer-Review Started
2025-04-27 00:12
First Decision by Editorial Office Director
2025-06-05 09:29
Return for Revision
2025-06-05 09:29
Revised
2025-06-16 17:47
Publication Fee Transferred
2025-06-20 07:46
Editorial Processing by Scientific Editor
2025-07-24 02:42
Final Academic Decision by Editor-in-Chief
Publication Technical Verification by Editorial Office Director
2025-07-24 08:27
Articles in Press
2025-07-24 08:27
Edit the Manuscript by Language Editor
Typeset the Manuscript
2025-08-15 03:14
Publish the Manuscript Online
2025-08-27 09:21
ISSN 1948-5182 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Meta-Analysis
Article Title Response rates, survival status and adverse events of placebo in randomized control trials for hepatocellular carcinoma: A meta-analysis
Manuscript Source Unsolicited Manuscript
All Author List Wei-Yu Chen, Qing Chen, Chen-Chen Wang, Chen-Yue Zhang, Si-Kun Chen, Zhi-Qiang Meng, Ping Han, Shu Dong and Qi-Wen Chen
ORCID
Author(s) ORCID Number
Wei-Yu Chen http://orcid.org/0009-0007-9265-7649
Qing Chen http://orcid.org/0000-0003-1765-9613
Chen-Chen Wang http://orcid.org/0000-0003-4930-3187
Zhi-Qiang Meng http://orcid.org/0000-0003-3593-6098
Qi-Wen Chen http://orcid.org/0000-0003-3141-1817
Funding Agency and Grant Number
Corresponding Author Qi-Wen Chen, MD, Department of Integrative Oncology, Fudan University Shanghai Cancer Center, No. 270 Dongan Road, Shanghai 200032, China. cqwly@hotmail.com
Key Words Hepatocellular carcinoma; Placebo; Randomized controlled trials; Response rates; Survival status; Adverse events
Core Tip While the therapeutic arm dominates hepatocellular carcinoma clinical trials, the placebo comparator serves as a critical but underutilized window into tumor biology. The natural course of hepatocellular carcinoma under placebo conditions remains poorly quantified, masking potential spontaneous stabilization mechanisms. Furthermore, placebo-associated adverse events in randomized controlled trials remain poorly characterized. Our meta-analysis addresses these gaps through systematically evaluated response rates, survival status and adverse events across placebo arms of hepatocellular carcinoma randomized controlled trials.
Publish Date 2025-08-27 09:21
Citation

Chen WY, Chen Q, Wang CC, Zhang CY, Chen SK, Meng ZQ, Han P, Dong S, Chen QW. Response rates, survival status and adverse events of placebo in randomized control trials for hepatocellular carcinoma: A meta-analysis. World J Hepatol 2025; 17(8): 108533

URL https://www.wjgnet.com/1948-5182/full/v17/i8/108533.htm
DOI https://dx.doi.org/10.4254/wjh.v17.i8.108533
Full Article (PDF) WJH-17-108533-with-cover.pdf